Reach Us +44-1625-708989
Renal Nerve Denervation: Nephrologists Perspective | 9148
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Renal nerve denervation: Nephrologists perspective

2nd International Conference on Nephrology & Therapeutics

Saravanan Bala

ScientificTracks Abstracts: J Nephrol Therapeutic

DOI: 10.4172/2161-0959.S1.009

I nadequately controlled hypertension has significant implications on adverse patient outcomes and healthcare cost. Renal Nerve Denervation (RND) is a non-pharmacological endovascular approach in treating hypertension. Two randomized studies have been published on RND that have shown reduction in systolic and diastolic blood pressure in 6 months. The studies have not analyzed mortality, renal or cardiovascular outcomes. The procedure involves ablation of the sympathetic nerves to the kidney which alters renal blood flow and decreases the afferent sympathetic outflow. The long term effects of these alterations in renal hemodynamics are unclear at this point. Despite the flaws in the study design, all the trials on revascularization of ARVD (Atherosclerotic renal vascular disease) have not shown any benefit over optimal medical therapy. However, a onetime procedure with minimal procedural risk might be an acceptable alternative to 2 or 3 additional life-long antihypertensive medications. Since the procedure has a direct effect on renal hemodynamics, it is extremely important for the Nephrologists to be part of the decision making process to choose the ideal candidate for RND. More information on safety and outcomes would be available after the SIMPLICITY-3 trial is published. If RND is approved in the United States, patient recruitment for the procedure should be performed only in Hypertension Specialty clinics which is staffed by a Nephrologist and a Cardiologist of whom one should be a hypertension specialist certified by the American Society of Hypertension.
Saravanan Bala graduated from Madras Medical College and pursued his Masters in public health at Wichita State University in Kansas. He completed his internal medicine residency and chief residency from Chicago Medical School. He graduated from Internal medicine and was inducted into Alpha Omega Alpha honors medical society for outstanding leadership and teaching. He got his Nephrology fellowship at Tulane University under the mentorship of Dr. Batuman. He currently practices Interventional Nephrology at Angiocare, Tucson and is part of the teaching faculty for the Nephrology Fellowship program at University of Arizona, Tucson.
Relevant Topics